Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)
Blood (2018)
  • Tycel J. Phillips, University of Michigan
  • Stephen D. Smith, Fred Hutchinson Cancer Research Center
  • Wojciech Jurczak, Jagiellonian University
  • Tadeusz Robak, Medical University of Łódź
  • Don Stevens, Norton Cancer Institute, Louisville, KY
  • Charles M. Farber, Summit Medical Group, Florham Park, NJ
  • John M. Pagel, Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA
  • Kami J. Maddocks, Ohio State University
  • Ian W. Flinn, Sarah Cannon Research Institute
  • Wieslaw W. Jedrzejczak, Department of Hematology, Medical University, Warsaw, Poland
  • Andre Goy, John Theurer Cancer Center at Hackensack-UMC, Hackensack, NJ
  • Pier Luigi Zinzani, University of Bologna
  • Jan Zaucha, Gdańsk Medical University
  • Morton Coleman, Cornell University
  • Tianling Chen, Acerta Pharma, South San Francisco, CA
  • Sun Ku Lee, Acerta Pharma, South San Francisco, CA
  • Wei Liang, Acerta Pharma, South San Francisco, CA
  • Anna Seto, Acerta Pharma, South San Francisco, CA
  • Michael Wang, University of Texas MD Anderson Cancer Center
Link
Disciplines
Publication Date
November 21, 2018
DOI
10.1182/blood-2018-99-110617
Citation Information
Tycel J. Phillips, Stephen D. Smith, Wojciech Jurczak, Tadeusz Robak, et al.. "Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)" Blood Vol. 132 (2018) p. 4144 - 4144
Available at: http://works.bepress.com/john-pagel/297/